Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily CSI China Internet Bull 2X Shares vs Novartis AG — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $18.2 (market cap $173.62M), while Novartis AG trades at $142.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 1546.9× Direxion Daily CSI China Internet Bull 2X Shares's market cap, and Novartis AG pays a 3.31% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily CSI China Internet Bull 2X Shares for 24 Days and Novartis AG for 82 Days on average.
| CWEB | NVS | |
|---|---|---|
Market Cap | $173.62M | $268.57B |
Volume | 551,726 | 1,532,573 |
Sector | Leveraged / Inverse | Health |
52-Week High | $55.62 | $168.62 |
52-Week Low | $17.39 | $121.80 |
Typical Hold Time | 24 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CWEB trades at $18.02, down 1.85% today amid bearish technical signals. The stock shows weak momentum with all 13 moving averages signaling sell, though oscillators are neutral. Recent news highlights China's AI ambitions and potential for China growth stocks to surge, providing thematic catalysts. Financial ratios remain undisclosed in current data.
Outlook hinges on China's tech sector recovery and AI growth narrative. Risks include geopolitical tensions and market volatility. The upcoming dividend of $0.07 in September 2026 offers income potential, but investors need clarity on fundamentals for sustained upside.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
